In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients

In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urg...

Full description

Bibliographic Details
Main Authors: Simon Heeke, Jonathan Benzaquen, Elodie Long-Mira, Benoit Audelan, Virginie Lespinet, Olivier Bordone, Salomé Lalvée, Katia Zahaf, Michel Poudenx, Olivier Humbert, Henri Montaudié, Pierre-Michel Dugourd, Madleen Chassang, Thierry Passeron, Hervé Delingette, Charles-Hugo Marquette, Véronique Hofman, Albrecht Stenzinger, Marius Ilié, Paul Hofman
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
tumor mutational burden
FoundationOne assay
Oncomine TML assay
lung cancer
melanoma
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/11/9/1271

Internet

https://www.mdpi.com/2072-6694/11/9/1271

Similar Items